Loading...
Market
What weight loss will VK2735 Phase 2 study achieve?
2
Resolution / Starting Odds
Less than 5% weight loss • 25%
5% to 10% weight loss • 25%
10% to 15% weight loss • 25%
More than 15% weight loss • 25%
Results published in clinical trial reports or scientific publications
Story
Viking's VK2735 Shows 8.2% Weight Loss with Placebo-Like Safety at ObesityWeek 2024
Nov 4, 2024, 10:57 AM
Viking Therapeutics reported positive early-stage clinical trial data for its oral obesity drug VK2735 at the ObesityWeek 2024 conference, exceeding expectations. The drug demonstrated a weight loss of up to 8.2% from baseline (6.8% placebo-adjusted) after 28 days of dosing with the 100 mg daily dose. VK2735 was well-tolerated, showing a safety profile similar to placebo, with no moderate or severe nausea reported even at the highest doses. Patients maintained weight loss long after the last dose. The company plans to initiate a Phase 2 study of the oral tablet formulation by the end of the year and discuss the clinical path forward with the FDA for the injectable formulation later in the quarter.
View original story
Similar markets
Mean weight loss < 5% • 25%
Mean weight loss 5% to 7% • 25%
Mean weight loss 7% to 9% • 25%
Mean weight loss > 9% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Below expectations • 25%
Study discontinued • 25%
Approved • 25%
Conditionally approved • 25%
Not approved • 25%
Approval pending • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%